{
  "name": "Servier Laboratories (Australia) Pty Ltd v GenRx Pty Ltd [2006] FCA 1763 (30 November 2006)",
  "austlii_url": "http://www.austlii.edu.au/au/cases/cth/FCA/2006/1763.html",
  "catchphrases": [
    {
      "text": "interlocutory injunction application",
      "id": "c0"
    },
    {
      "text": "respondent about to market the generic equivalent of applicant's product",
      "id": "c1"
    },
    {
      "text": "respondent's product only registered by therapeutic goods administration for two of the three indications for which applicant's product registered",
      "id": "c2"
    },
    {
      "text": "subsequent to filing of application tga registered third indication",
      "id": "c3"
    },
    {
      "text": "costs",
      "id": "c4"
    }
  ],
  "sentences": [
    {
      "text": "1 The applicant is the owner of the therapeutic drug Coversyl (active ingredient - Perindopril) which has three registered indications for treatment: hypertension, chronic heart fatigue and coronary artery disease.",
      "id": "s0"
    },
    {
      "text": "The respondent is the producer of perindopril erbumine products are the generic version of Coversyl.",
      "id": "s1"
    },
    {
      "text": "2 The applicant claims that the respondent circulated advertising material promoting its products as a \"genuine alternative\" to Coversyl Perindopril, thereby representing that the products were substitutable for each of the three registered indications outlined above.",
      "id": "s2"
    },
    {
      "text": "The Product Information for the Respondent's products indicates that it is not an authorised indication for coronary artery disease (the applicant's third registered indication).",
      "id": "s3"
    },
    {
      "text": "3 The respondent obtained a listing from the Pharmaceutical Benefits Scheme effective from 1 December 2006, which required the respondent to be in an immediate position to supply the market from that date.",
      "id": "s4"
    },
    {
      "text": "The applicant sought an interlocutory injunction preventing the respondent from representing that its products were substitutable with Coversyl to treat coronary artery disease.",
      "id": "s5"
    },
    {
      "text": "4 Immediately prior to the scheduled commencement of the interlocutory hearing, the respondent had communication from the Therapeutic Goods Administration that its products had been registered for the third indication.",
      "id": "s6"
    },
    {
      "text": "As such, the applicant no longer has a claim against the respondents for misleading and deceptive conduct.",
      "id": "s7"
    },
    {
      "text": "Therefore, the only matter for me to decide is one of costs.",
      "id": "s8"
    },
    {
      "text": "5 The considerations which apply when a matter has otherwise been resolved but the parties seek an order for costs has recently been discussed by me in Oxford Funding Proprietary Limited v Oxford Asia Pacific Investments Proprietary Limited (No 2) [2006) FCA 1542 at par [5].",
      "id": "s9"
    },
    {
      "text": "6 In the present case the dispute arose in circumstances of great urgency.",
      "id": "s10"
    },
    {
      "text": "The parties are fierce trade rivals, and understandably concerned to protect their commercial interests.",
      "id": "s11"
    },
    {
      "text": "The Court should not be too ready to dictate in hindsight a particular course of conduct which the parties could or should have taken.",
      "id": "s12"
    },
    {
      "text": "7 I think the applicant acted reasonably in initiating proceedings to forestall what was arguably, in its view, misleading and deceptive conduct by the respondent which could be seriously damaging.",
      "id": "s13"
    },
    {
      "text": "The respondent, on the other hand, proffered firm assurances which would meet the applicant's concerns.",
      "id": "s14"
    },
    {
      "text": "As events have turned out, those assurances have been substantiated.",
      "id": "s15"
    },
    {
      "text": "It is possible that the respondent might have offered more corroborating detail in its letter of today's date.",
      "id": "s16"
    },
    {
      "text": "However, that was a matter for judgment which had to be made quickly and under pressure.",
      "id": "s17"
    },
    {
      "text": "Given its legitimate concern about confidentiality of dealings with the Therapeutic Goods Administration, I do not think that the respondent acted unreasonably, although it might have acted differently.",
      "id": "s18"
    },
    {
      "text": "8 In the circumstances, I do not propose to make any order as to costs.",
      "id": "s19"
    },
    {
      "text": "The substantive application will be dismissed.",
      "id": "s20"
    },
    {
      "text": "I certify that the preceding eight (8) numbered paragraphs are a true copy of the Reasons for Judgment herein of the Honourable Justice Heerey.",
      "id": "s21"
    },
    {
      "text": "Associate:\n\nDated: 30 November 2006\n\n Counsel for the Applicant: D Shavin QC and I Horak \n \n Solicitors for the Applicant: Clayton Utz \n \n Counsel for the Respondent: S McVicar \n \n Solicitors for the Respondent: Freehills \n \n Date of Hearing: 30 November 2006 \n \n Date of Judgment: 30 November 2006 \n\n\n\n \n\n \n AustLII: Copyright Policy | Disclaimers | Privacy Policy | Feedback \n URL: http://www.austlii.edu.au/au/cases/cth/FCA/2006/1763.html",
      "id": "s22"
    }
  ]
}